<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39452784</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-0817</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>19</Day></PubDate></JournalIssue><Title>Pathogens (Basel, Switzerland)</Title><ISOAbbreviation>Pathogens</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of an Infection Control Program Among the Ysleta del Sur Pueblo in Preventing COVID-19-Related Hospitalizations and Deaths.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">913</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pathogens13100913</ELocationID><Abstract><AbstractText>In response to the SARS-CoV-2 pandemic, the United States declared a state of emergency and implemented large-scale shutdowns and public health initiatives to prevent overwhelming public resources. The success of these prevention methods remains unresolved as restrictions and implementation varied from national, state, and local levels. Despite national and local regulations, individual adherence to preventative guidelines presented an additional layer of variability. Cases of COVID-19 continued to rise and fall over a two-year period on a national level, despite masking recommendations, ease of testing, and availability of vaccines. The Ysleta del Sur Pueblo is a Native American tribal community and sovereign nation located in El Paso, Texas. Speaking Rock Entertainment Center is a major business operated by the tribe, employing many tribal and non-tribal members from the El Paso area. Following nationwide re-openings of non-essential businesses, Speaking Rock implemented an infection control program with strict adherence to recommendations provided by the Center for Disease Control and Prevention (CDC) and additional disease control. This response would result in a fully vaccinated workforce within the wider community of El Paso, where the vaccination rate was less than 80%. Herein, we examine the efficacy of these measures and report on the success of the program resulting in zero hospitalizations or deaths compared with rates of 1 in 250 and 1 in 40, respectively, in the surrounding community.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Torres</LastName><ForeName>Cameron M</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0003-0564-7535</Identifier><AffiliationInfo><Affiliation>Department of Biological Sciences, University of Texas at El Paso, El Paso, TX 79968, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aparicio</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><Identifier Source="ORCID">0009-0003-4820-4651</Identifier><AffiliationInfo><Affiliation>Speaking Rock Entertainment, Wellness Response Department, Ysleta del Sur Pueblo, El Paso, TX 79907, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calzada</LastName><ForeName>Gabriela</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Speaking Rock Entertainment, Wellness Response Department, Ysleta del Sur Pueblo, El Paso, TX 79907, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mena</LastName><ForeName>Ascension</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Speaking Rock Entertainment, Wellness Response Department, Ysleta del Sur Pueblo, El Paso, TX 79907, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spencer</LastName><ForeName>Charles T</ForeName><Initials>CT</Initials><Identifier Source="ORCID">0000-0001-8121-8463</Identifier><AffiliationInfo><Affiliation>Department of Biological Sciences, University of Texas at El Paso, El Paso, TX 79968, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>SC1 AI148753</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Private donation</GrantID><Agency>Speaking Rock Entertainment Center</Agency><Country /></Grant><Grant><GrantID>1SC1AI148753-01A1</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pathogens</MedlineTA><NlmUniqueID>101596317</NlmUniqueID><ISSNLinking>2076-0817</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">native American</Keyword><Keyword MajorTopicYN="N">pandemic response</Keyword></KeywordList><CoiStatement>This report presents data collected by the Wellness Response Department of Speaking Rock Entertainment Group. The data were analyzed by CMT with one semester funding from Speaking Rock Entertainment Group. Publication costs were partially covered by Speaking Rock Entertainment Group. Dr. Spencer received no direct or indirect funding from Speaking Rock Entertainment and oversaw the validity of this report.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>10</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39452784</ArticleId><ArticleId IdType="pmc">PMC11510218</ArticleId><ArticleId IdType="doi">10.3390/pathogens13100913</ArticleId><ArticleId IdType="pii">pathogens13100913</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>V’kovski P., Kratzel A., Steiner S., Stalder H., Thiel V. Coronavirus biology and replication: Implications for SARS-CoV-2. Nat. Rev. Microbiol. 2021;19:155–170. doi: 10.1038/s41579-020-00468-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00468-6</ArticleId><ArticleId IdType="pmc">PMC7592455</ArticleId><ArticleId IdType="pubmed">33116300</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorbalenya A., Baker S., Baric R.S., de Groot R., Drosten C., Gulyaeva A.A., Haagmans B., Lauber C., Leontovich A.M., Neuman B.W., et al. The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Rev. Microbiol. 2020;5:536–544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095448</ArticleId><ArticleId IdType="pubmed">32123347</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B., Guo H., Zhou P., Shi Z.L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2021;19:141–154. doi: 10.1038/s41579-020-00459-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00459-7</ArticleId><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>Khadka R.B., Bhandari R., Gyawali R., Neupane B., Pant D. Epidemiology and Pathogenesis of Coronavirus Disease (COVID-19) Nov. Res. Microbiol. J. 2020;4:675–687.</Citation></Reference><Reference><Citation>Sharma A., Ahmad Farouk I., Lal S.K. COVID-19: A review on the novel coronavirus disease evolution, transmission, detection, control and prevention. Viruses. 2021;13:202. doi: 10.3390/v13020202.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13020202</ArticleId><ArticleId IdType="pmc">PMC7911532</ArticleId><ArticleId IdType="pubmed">33572857</ArticleId></ArticleIdList></Reference><Reference><Citation>Bushmaker T., Yinda C.K., Morris D.H., Holbrook M.G., Gamble A., Adney D., Bushmaker C., van Doremalen N., Fischer R.J., Plowright R.K., et al. Comparative Aerosol and Surface Stability of SARS-CoV-2 Variants of Concern. Emerg. Infect. Dis. 2023;29:1033–1037. doi: 10.3201/eid2905.221752.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2905.221752</ArticleId><ArticleId IdType="pmc">PMC10124653</ArticleId><ArticleId IdType="pubmed">37054984</ArticleId></ArticleIdList></Reference><Reference><Citation>Amirfakhryan H., Safari F. Outbreak of SARS-CoV2: Pathogenesis of infection and cardiovascular involvement. Hellenic. J. Cardiol. 2021;62:13–23. doi: 10.1016/j.hjc.2020.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hjc.2020.05.007</ArticleId><ArticleId IdType="pmc">PMC7275139</ArticleId><ArticleId IdType="pubmed">32522617</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson C.B., Farzan M., Chen B., Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 2022;23:3–20. doi: 10.1038/s41580-021-00418-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00418-x</ArticleId><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn J.H., Kim J., Hong S.P., Choi S.Y., Yang M.J., Ju Y.S., Kim Y.T., Kim H.M., Rahman M.T., Chung M.K., et al. Nasal ciliated cells are primary targets for SARS-CoV-2 replication in the early stage of COVID-19. J. Clin. Investig. 2021;131:e148517. doi: 10.1172/JCI148517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI148517</ArticleId><ArticleId IdType="pmc">PMC8245175</ArticleId><ArticleId IdType="pubmed">34003804</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou Y.J., Okuda K., Edwards C.E., Martinez D.R., Asakura T., Dinnon K.H., Kato T., Lee R.E., Yount B.L., Mascenik T.M., et al. SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. Cell. 2020;182:429–446.e14. doi: 10.1016/j.cell.2020.05.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.05.042</ArticleId><ArticleId IdType="pmc">PMC7250779</ArticleId><ArticleId IdType="pubmed">32526206</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan M., Yoo S.J., Clijsters M., Backaert W., Vanstapel A., Speleman K., Lietaer C., Choi S., Hether T.D., Marcelis L., et al. Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb. Cell. 2021;184:5932–5949.e15. doi: 10.1016/j.cell.2021.10.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.10.027</ArticleId><ArticleId IdType="pmc">PMC8564600</ArticleId><ArticleId IdType="pubmed">34798069</ArticleId></ArticleIdList></Reference><Reference><Citation>Alomair B.M., Al-Kuraishy H.M., Al-Gareeb A.I., Al-Buhadily A.K., Alexiou A., Papadakis M., Alshammari M.A., Saad H.M., Batiha G.E. Mixed storm in SARS-CoV-2 infection: A narrative review and new term in the COVID-19 era. Immun. Inflamm. Dis. 2023;11:e838. doi: 10.1002/iid3.838.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.838</ArticleId><ArticleId IdType="pmc">PMC10132185</ArticleId><ArticleId IdType="pubmed">37102645</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395:507–513. doi: 10.1016/S0140-6736(20)30211-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30211-7</ArticleId><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Valle D.M., Kim-Schulze S., Huang H.H., Beckmann N.D., Nirenberg S., Wang B., Lavin Y., Swartz T.H., Madduri D., Stock A., et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 2020;26:1636–1643. doi: 10.1038/s41591-020-1051-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1051-9</ArticleId><ArticleId IdType="pmc">PMC7869028</ArticleId><ArticleId IdType="pubmed">32839624</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J.T., Leung K., Leung G.M. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: A modeling study. Lancet. 2020;395:689–697. doi: 10.1016/S0140-6736(20)30260-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30260-9</ArticleId><ArticleId IdType="pmc">PMC7159271</ArticleId><ArticleId IdType="pubmed">32014114</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui D.S., Azhar E.I., Madani T.A., Ntoumi F., Kock R., Dar O., Ippolito G., Mchugh T.D., Memish Z.A., Drosten C., et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China. Int. J. Infect. Dis. 2020;91:264–266. doi: 10.1016/j.ijid.2020.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.01.009</ArticleId><ArticleId IdType="pmc">PMC7128332</ArticleId><ArticleId IdType="pubmed">31953166</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Coronavirus Disease 2019 Situation Report 51-11th March 2020. WHO Bull. 2020;2019:2633.</Citation></Reference><Reference><Citation>Kuldeep D., Sharun K., Ruchi T., Shubhankar S., Sudipta B., Yashpal S.M., Karam P.S., Wanpen C.D., Katterine B.A., Alfonso J.R.M. Coronavirus Disease 2019-COVID-19. Clin. Microbiol. Rev. 2020;33:10-1128.</Citation></Reference><Reference><Citation>Ayittey F.K., Ayittey M.K., Chiwero N.B., Kamasah J.S., Dzuvor C. Economic impacts of Wuhan 2019-nCoV on China and the world. J. Med. Virol. 2020;92:473–475. doi: 10.1002/jmv.25706.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25706</ArticleId><ArticleId IdType="pmc">PMC7166799</ArticleId><ArticleId IdType="pubmed">32048740</ArticleId></ArticleIdList></Reference><Reference><Citation>Bliss F., City H., Dulce A., Elizario S. El Paso Strong COVID Tracker.  [(accessed on 30 January 2023)].  Available online:  https://www.epstrong.org/results.php.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention . COVID Data Tracker. U.S. Department of Health and Human Services, CDC; Atlanta, GA, USA: 2023.</Citation></Reference><Reference><Citation>CDC . The Science of Masking to Control COVID-19 Most SARS-CoV-2 Infections Are Spread by People without Symptoms. CDC; Atlanta, GA, USA: 2020.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention-CDC . Guidance for Cleaning and Disinfecting Public Spaces. CDC; Atlanta, GA, USA: 2020. pp. 1–9. Coronavirus Disease 2019.</Citation></Reference><Reference><Citation>U.S. Census Bureau 2020. Profiles.  [(accessed on 2 October 2024)]; Available online:  https://data.census.gov/profile/Ysleta_del_Sur_Pueblo_and_Off-Reservation_Trust_Land,_TX?g=2500000US4755.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention . ACIP Evidence to Recommendations (EtR) for Use of Bivalent COVID-19 Vaccine Booster Doses under an Emergency Use Authorization. U.S. Department of Health and Human Services, CDC; Atlanta, GA, USA: 2023.</Citation></Reference><Reference><Citation>Baranova A., Cao H., Teng S., Zhang F. A phenome-wide investigation of risk factors for severe COVID-19. J. Med. Virol. 2023;95:e28264. doi: 10.1002/jmv.28264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28264</ArticleId><ArticleId IdType="pmc">PMC9874597</ArticleId><ArticleId IdType="pubmed">36316288</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhamad S.A., Ugusman A., Kumar J., Skiba D., Hamid A.A., Aminuddin A. COVID-19 and Hypertension: The What, the Why, and the How. Front. Physiol. 2021;12:665064. doi: 10.3389/fphys.2021.665064.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2021.665064</ArticleId><ArticleId IdType="pmc">PMC8126692</ArticleId><ArticleId IdType="pubmed">34012410</ArticleId></ArticleIdList></Reference><Reference><Citation>Baghani M., Fathalizade F., Loghman A.H., Samieefar N., Ghobadinezhad F., Rashedi R., Baghsheikhi H., Sodeifian F., Rahimzadegan M., Akhlaghdoust M. COVID-19 vaccine hesitancy worldwide and its associated factors: A systematic review and meta-analysis. Sci. One Health. 2023;2:100048. doi: 10.1016/j.soh.2023.100048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.soh.2023.100048</ArticleId><ArticleId IdType="pmc">PMC11262288</ArticleId><ArticleId IdType="pubmed">39077035</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman P.A., Dinh D.A., Nyoni T., Allan K., Fantus S., Williams C.C., Tepjan S., Reid L., Guta A. COVID-19 Vaccine Hesitancy and Under-Vaccination among Marginalized Populations in the United States and Canada: A Scoping Review. J. Racial Ethn. Health Disparities. 2023 doi: 10.1007/s40615-023-01882-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40615-023-01882-1</ArticleId><ArticleId IdType="pubmed">38117443</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention . COVID-19 Vaccines for People Who Are NOT Moderately or Severely Immunocompromised. CDC; Atlanta, GA, USA: 2024.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>